Videos
Early Relapsed Multiple Myeloma: What’s Changing in 2025 | Research Breakthroughs from ASCO & EHA
Are you or a loved one navigating a multiple myeloma relapse after one to three prior treatments?
In this video, Dr. Joseph Mikhael, Chief Medical Officer of the International…
Videos
Dr. Joseph Mikhael's presentation reveals a transformative period in multiple myeloma treatment, with June 2025 marking unprecedented breakthroughs across the disease spectrum. The research demonstrates a paradigm shift toward precision medicine, where MRD (minimal residual disease) negativity is…
Videos
Newly Diagnosed Multiple Myeloma: What’s Changing in 2025? | ASCO & EHA
Dr. Joseph Mikhael (IMF Chief Medical Officer) breaks down the most important updates from ASCO and EHA for newly diagnosed multiple myeloma patients. Learn how your first treatment can shape long-term outcomes…
Videos
DOWNLOAD SLIDES
News Article
The International Myeloma Foundation Mourns the Loss of Accomplished Attorney and Longtime Board Member Benson Klein
STUDIO CITY, CA, July 29, 2025—Today, the International Myeloma Foundation (IMF) announces with great sadness the passing of our beloved and…
Videos
Exploring Linvoseltamab (LINVO) and Carfilzomib (CFZ) combination in relapsed/refractory multiple myeloma (RRMM) via LINKER-MM2 trial. Assessing safety, efficacy, and pharmacokinetics with promising initial outcomes: high response rates (ORR 91-100%), manageable toxicity (neutropenia,…
News Article
EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma
On Friday, July 25, the European Union (EU) approved Sarclisa (isatuximab-irfc) to be used "in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for…
Videos
The ADVANCE study compared DKRd (daratumumab, carfilzomib, lenalidomide, dexamethasone) with KRd (carfilzomib, lenalidomide, dexamethasone) in newly diagnosed multiple myeloma patients. Primary endpoint was MRD negativity, showing DKRd significantly outperformed KRd (59% vs 36%). Safety profiles…
News Article
July 24, 2025—According to a press release from GSK, Blenrep (belantamab mafodotin) has been approved "in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at…
Videos
Answering Your Myeloma Clinical Trial Questions
Thinking About a Myeloma Clinical Trial? Get Real Answers from Experts and Patients
Join Dr. Joseph Mikhael (Chief Medical Officer, International Myeloma Foundation), long-term survivor Thomas Goode, and Brian McMahon (Founder of SparkCures) as…